<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214393</url>
  </required_header>
  <id_info>
    <org_study_id>3650</org_study_id>
    <nct_id>NCT03214393</nct_id>
  </id_info>
  <brief_title>Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy</brief_title>
  <official_title>Role of Maternal Anticardiolipin and Anti-B2 Glycoprotein I Antibodies in Correlation With Fetal Doppler in Prediction of Adverse Pregnancy Outcome in Patients With Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relation of certain maternal serum antibodies to Doppler changes will be studied in cases
      suffering from hypertension with pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment will be done for maternal serum anti-beta 2 glycoprotein 1 antibodies and
      anticardiolipin antibodies in cases of preeclampsia after 32 weeks of pregnancy. In addition,
      fetal Doppler changes will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of cases that develop severe pre-eclampsia</measure>
    <time_frame>It will be calculated after 1 year from the start of the study</time_frame>
    <description>percentage of cases that develop severe pre-eclampsia will be assessed by an investigator</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Pre-Eclampsia</arm_group_label>
    <description>pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Doppler</intervention_name>
    <description>Doppler will be done to pregnant women with Pre-Eclampsia</description>
    <arm_group_label>Pre-Eclampsia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum antibodies</intervention_name>
    <description>serum antibodies will be measured for pregnant women with Pre-Eclampsia</description>
    <arm_group_label>Pre-Eclampsia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant females 32 weeks gestation or more with pre-eclampsia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women 32 weeks or more gestational age

          -  Pre-eclampsia

          -  Singleton pregnancy

        Exclusion Criteria:

          -  Intrauterine fetal death

          -  Fetus with apparent congenital anomalies

          -  Pregnant females with other medical disorders

          -  History of essential hypertension.

          -  History of antepartum hemorrhage.

          -  History of rupture of membranes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doaa Sh Belal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo U</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doaa Sh Belal, MD</last_name>
    <phone>0020223682030</phone>
    <email>doaash@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology</name>
      <address>
        <city>Cairo</city>
        <state>Greater Cairo</state>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doaa Belal, MD</last_name>
      <phone>0020223682030</phone>
      <email>doaash@live.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Doaa Shafie Belal</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

